振芯科技(300101.SZ):擬在海南省瓊海市投設全資子公司
格隆匯 3 月 22日丨振芯科技(300101.SZ)公佈,2021年3月19日,公司第五屆董事會第四次會議審議通過了《關於對外投資設立全資子公司的議案》,公司董事會同意在海南省瓊海市投資設立全資子公司,註冊資本為10000萬元,由公司以自有貨幣資金出資。
此次設立全資子公司,是為了發揮公司在集成電路、衞星綜合應用、視頻光電等電子信息技術產業積累的技術優勢和資源,藉助海南自貿港貿易、投資、跨境資金流動等方面的政策優勢,抓住海南全方位對外開放和改革先行示範區域的歷史機遇,為公司的發展和業務增長創造更多的機遇和有利條件,助推公司技術創新、拓展海外市場、提升公司長期盈利能力和綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.